James Hughes has served as an expert witness in a variety of antitrust, regulatory, labor discrimination, and product misrepresentation matters in industries that span healthcare, life sciences, commodities, and services. His recent work has focused on class certification issues in the pharmaceutical industry.
Professor Hughes provided expert testimony In re Pharmaceutical Industry Average Wholesale Price Litigation and In re Skelaxin (Metaxalone) Antitrust Litigation, as well as in several relator cases. He has consulted in matters involving the prescription pharmaceuticals Cipro, Cardizem CD, Neurontin, Rezulin, Procardia XL, and Provigil.
Professor Hughes researches issues in law and economics, pharmaceuticals, healthcare, regulation, labor economics, and antitrust economics. He has studied how generic prescription drug laws may affect innovation rates in research pharmaceutical companies, and the impact of tobacco taxes on healthcare utilization.
At Bates College, Professor Hughes received awards for excellence in teaching. Previously, he was on the faculty at Amherst College and the State University of New York at Albany. His articles have appeared in numerous scholarly journals, including the American Economic Review, the International Review of Law and Economics, and the Journal of Law and Economics.
In re Novartis and Par Antitrust Litigation
In re Niaspan Antitrust Litigation
Cornerstone Research Nominated for Global Competition Review Awards 2020
In re Intuniv Antitrust Litigation
Cornerstone Research Staff and Expert Sign Amici Curiae Brief for U.S. First Circuit
Cornerstone Research Coauthors Antitrust Amicus Curiae Brief for U.S. Third Circuit
In re Skelaxin (Metaxalone) Antitrust Litigation
Average Wholesale Price Litigation
- In re Novartis and Par Antitrust Litigation
- In re Niaspan Antitrust Litigation
- In re Intuniv Antitrust Litigation
- Cornerstone Research Staff and Expert Sign Amici Curiae Brief for U.S. First Circuit
- Cornerstone Research Coauthors Antitrust Amicus Curiae Brief for U.S. Third Circuit
- In re Skelaxin (Metaxalone) Antitrust Litigation
- Average Wholesale Price Litigation